Biotech Startups

Biogen develops and markets therapies for spinal muscular atrophy (SMA), including FDA-approved treatments and the investigational ThecaFlex DRx System, an implantable intrathecal drug delivery device. The company serves patients and families affected by SMA and other neuromuscular conditions globally.

1 investor

1 investor

Aldeyra Therapeutics is a biopharmaceutical company developing therapies for eye diseases and other conditions. The company is led by a board of experienced pharmaceutical and life sciences executives.

1 investor

AlgaeCytes cultivates microalgae using enclosed photobioreactors to produce high-value natural ingredients, including Omega-3 EPA oils, for the health and wellness industry. The company targets sustainable alternatives to fish oil and other conventional ingredient sources for supplements, food, and cosmetics applications.

1 investor

Algaeing produces textile dyes and fibers from algae, a renewable microorganism, replacing synthetic dyes in the fashion industry. The company partners with algae growers to create sustainable, biodegradable materials that retain algae's botanical properties.

1 investor

Alganex supplies certified organic Spirulina platensis powder, a nutrient-dense microalgae product cultivated in Italy, for use as a food supplement, functional ingredient, animal feed component, and cosmetic ingredient across B2B markets. The powder is valued for its high protein content, essential amino acids, and phycocyanin (blue pigment) concentration.

1 investor

AlgenAir produces the aerium, a home device that uses algae to reduce indoor carbon dioxide and increase oxygen while generating organic fertilizer from the algae byproduct. It serves household users seeking improved air quality and plant enthusiasts.

1 investor

Algenex develops proprietary baculovirus expression technologies and manufacturing processes for producing recombinant proteins used in pharmaceuticals and diagnostics. The company harnesses insect-based bioreactors to enable cost-effective, scalable production of complex protein-based products.

1 investor

Algenist develops algae-based skincare products, including anti-aging creams, serums, and treatments built around its proprietary Alguronic Acid compound derived from microalgae. It sells clinically tested cosmetic products directly to consumers.

1 investor

Algentech uses a proprietary chloroplast-based plant bioproduction platform to manufacture biobased active ingredients and biomaterials such as melanin, antimicrobials, and nucleic acids. It serves industrial partners in the cosmetics, pharmaceutical, and food sectors with low-waste, animal-free production.

1 investor

Algiax Pharmaceuticals is a clinical-stage biotech company developing small-molecule GABAA receptor modulators to treat neuropathic pain and other conditions with high unmet medical need. The company's lead candidate AP-325 is in Phase 2 clinical trials for chronic neuropathic pain.

1 investor

Algicel produces Azora, a natural astaxantin dietary supplement extracted from the freshwater microalga Haematococcus Pluvialis grown in the Azores, sold as softgel capsules and an emulsion. The products are marketed as antioxidant and anti-inflammatory supplements for immune, cardiovascular, joint, and cellular health for children and adults in Portugal.

1 investor

Algiplex develops synthetic microbial ecosystems designed to boost microalgae biomass yields for algae producers, improving culture growth rate and resistance to culture crash events with minimal additional nutrient or energy costs. The company operates in the biotechnology and bioproduction sector.

1 investor

Algocell is an AI-powered bioprocess modeling platform that combines mechanistic bioprocess engineering with machine learning to build Digital Twins and hybrid models, letting cell-based companies simulate and optimize production in-silico and reduce physical trial-and-error experiments. It serves precision fermentation, cultivated food, and cell culture companies across foodtech, biotech, and pharmaceuticals, supporting R&D, scale-up, and in-production optimization.

1 investor

Algonist is a pre-clinical stage biotechnology company developing novel small molecule drugs to treat chronic pain without addiction risk. The company targets the large unmet medical need of chronic pain management, particularly in patients who fail standard analgesic treatments.

1 investor

Clinical stage company focused on developing therapies for viral diseases

1 investor

Allentown designs and manufactures laboratory equipment for washing and drying animal cages, racks, bottles, and related research facility supplies. The company offers multiple washer series including EQUINOX, BetterBuilt, and related models tailored for animal research facilities.

1 investor

Allero Therapeutics is a biotech company focused on immunotherapy solutions for allergy and immune-mediated disorders, particularly Celiac Disease. The company is led by experienced pharmaceutical and biotech executives with deep expertise in immunotherapy R&D and allergen management.

1 investor

Alleva Animal Health develops and supplies parasite control products for livestock and pets, sold through rural veterinary practices, with brands including BOSS, CATOLYST, TURBO, and EPRISURE. The company operates a formulation laboratory and serves veterinarians, farmers, and pet owners across New Zealand and Australia.

1 investor

Allied Carbon Solutions develops and manufactures sophorolipids, a natural biosurfactant, with applications in livestock feed and emulsifiers, personal care yeast-fermentation extracts, and agricultural biostimulants. The company conducts research and production of biosurfactant-based ingredients for the agriculture, animal husbandry, and personal care industries.

1 investor

Allied Microbiota applies biotechnology to remediate soil, water, and wastewater contamination, and enables beneficial reuse of large-volume waste streams.

1 investor

Alligator Bioscience AB is a biotechnology company whose shares are listed on NASDAQ Stockholm (Small Cap) under the ticker ATORX. This page presents investor information about the company's stock and shareholder register.

1 investor

Allinaire Therapeutics is developing humanized anti-EMAP II monoclonal antibodies as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH) and other cardiopulmonary diseases such as COPD and viral-induced acute lung injury. The company was founded on technology licensed from Indiana University.

1 investor

Acquired by Pasithea Therapeutics

1 investor